Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Johnson & Johnson : Biosense Webster Collaborates to Bring Innovative Solutions to Electrophysiologists Around the World

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/09/2012 | 03:05pm CET

Biosense Webster, Inc., the worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced today the execution of strategic collaboration agreements with two leading global imaging companies, GE Healthcare and Siemens Healthcare.

The announcement was made during the Heart Rhythm Society's (HRS) 33rd Annual Scientific Sessions. HRS 2012, the largest global conference for electrophysiologists, is being held in Boston from May 9-12, 2012.

Biosense Webster, Inc. has developed an image integration solution for electrophysiology (EP) labs around the world. This solution integrates real-time x-ray images, from Siemens Healthcare and GE Healthcare X-Ray systems, into the company's market leading CARTO® 3, 3D Electroanatomical Mapping & Ablation System. Under the terms of the two agreements, Biosense Webster, Inc. plans to offer an integrated solution, compatible with both manufacturers' fluoroscopy systems, in 2012.

"Minimizing x-ray exposure for patients and clinicians has long been a focus of healthcare technology manufacturers," said Shlomi Nachman, Worldwide President, Cardiovascular Care franchise. "These two important strategic agreements will allow Biosense Webster to address the growing need to combine multiple images from different systems in the EP lab into a single display on our CARTO® 3 System."

These latest agreements mark a significant step towards Biosense Webster, Inc.'s vision of providing a comprehensive integrated lab solution to electrophysiologists and hospitals around the world. GE Healthcare and Siemens Healthcare collectively, represent over 50% of the installed base of X-Ray systems across the globe.

"These strategic collaborations and the resulting technology advancements, continue our commitment to bringing innovation to the Cardiac Electrophysiology community so they may better serve their patients and protect themselves," said Nachman.

About AF and cardiac ablation

Atrial Fibrillation is the most prevalent arrhythmia, and is a leading cause of stroke among people 65 years and older. Worldwide, it is estimated that 20 million people have AF, yet only approximately 130,000 are treated with ablation every year. The public health implications of AF are a growing concern because those with AF are at an increased risk of morbidity and mortality as well as a reduced quality of life.

Most patients with AF today are treated with anti-arrhythmic drugs (AADs), even though about half of them are refractory to these drugs. During cardiac ablation, energy is delivered through the catheter to those areas of the heart muscle causing the abnormal heart rhythm. This energy "disconnects" the pathway of the abnormal rhythm. Cardiac ablation is a very common treatment for "simple" arrhythmias, like Wolff-Parkison-White Syndrome and atrioventricular nodal re-entry tachycardia (AVNRT), and is increasingly being used for more complex arrhythmias like ventricular tachycardia and atrial fibrillation. In the US, ThermoCool® Navigation Catheters are approved for drug refractory recurrent symptomatic paroxysmal atrial fibrillation, when used with CARTO® Systems (excluding NAVISTAR® RMT THERMOCOOL® Catheter).

About Biosense Webster, Inc.

Biosense Webster, Inc., pioneered EP diagnostic catheters more than 20 years ago and continues to lead the industry as an innovative provider of advanced diagnostic, therapeutic, and mapping tools. As the leader in navigation systems and ablation therapy, Biosense Webster, Inc. has technology that includes the largest installed base of navigation systems worldwide in leading hospitals and teaching institutions. For more information about Biosense Webster and its products, please visit: www.biosensewebster.com (this site is intended for US visitors only).

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Biosense Webster, Inc. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; changes to governmental laws and regulations and domestic and foreign health care reforms; trends toward health care cost containment; and increased scrutiny of the health care industry by government agencies. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2012. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Neither Biosense Webster, Inc. nor Johnson & Johnson undertake to update any forward-looking statements as a result of new information or future events or developments.

For Biosense Webster, Inc.
Sandra Pound, 908-218-2720
m: 908-432-2829
Spound@its.jnj.com


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 JOHNSON & JOHNSON : The Woodrow Wilson Center (WWC) - Discussion
12/02 HIP DAMAGES : Jury tells J&J to pay another $1 billion
12/02 JOHNSON & JOHNSON : to pay $1 billion for faulty hip implants
12/02 JOHNSON & JOHNSON : J&J ordered to pay record $1 billion for faulty hip implants
12/02 JOHNSON & JOHNSON : Dallas Jury Returns $1 Billion-Plus Verdict in Defective DeP..
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/29 WPP : Acquires US Company Promotion Execution Partners
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
More news
Sector news : Pharmaceuticals - NEC
12/02 Pharma execs weigh in on possible changes under Trump
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
12/01 GLAXOSMITHKLINE : GSK biotech asthma drug wins UK approval after extra price cut
12/01 PERRIGO : Cohen's SAC Capital in $135 million settlement with Elan investors
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
12/02 J&J Actelion bid reportedly tops $250/share
12/02 GILEAD : M&A Coming Soon
12/02 WALL STREET BREAKFAST : Non-Farm Payrolls In Focus
12/01 Johnson & Johnson hit with $1B-plus jury verdict on faulty hip implants
12/01 With 2016 Nearing A Close, Our Dividend Growth Portfolio Is Up Almost 10%
Advertisement
Financials ($)
Sales 2016 72 061 M
EBIT 2016 22 017 M
Net income 2016 16 371 M
Finance 2016 18 064 M
Yield 2016 2,80%
P/E ratio 2016 18,94
P/E ratio 2017 16,70
EV / Sales 2016 3,98x
EV / Sales 2017 3,70x
Capitalization 304 591 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 126 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer
Susan L. Lindquist Independent Director
Charles O. Prince Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON9.00%304 591
PFIZER INC.-2.01%191 942
ROCHE HOLDING LTD.-19.61%188 878
NOVARTIS AG-19.07%178 737
MERCK & CO., INC.15.85%168 544
SANOFI-4.20%103 510
More Results